Safety and efficacy of multipotent adult progenitor cells in acute ischaemic stroke (MASTERS): a randomised, double-blind, placebo-controlled, phase 2 trial

医学 安慰剂 祖细胞 冲程(发动机) 内科学 骨髓 外科 干细胞 病理 遗传学 机械工程 生物 工程类 替代医学
作者
David C. Hess,Lawrence R. Wechsler,Wayne M. Clark,Sean I. Savitz,Gary A. Ford,David Chiu,Dileep R Yavagal,Ken Uchino,David S. Liebeskind,Alexander P. Auchus,Souvik Sen,Cathy Sila,Jeffrey Vest,Robert W. Mays
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:16 (5): 360-368 被引量:360
标识
DOI:10.1016/s1474-4422(17)30046-7
摘要

Background Multipotent adult progenitor cells are a bone marrow-derived, allogeneic, cell therapy product that modulates the immune system, and represents a promising therapy for acute stroke. We aimed to identify the highest, well-tolerated, and safest single dose of multipotent adult progenitor cells, and if they were efficacious as a treatment for stroke recovery. Methods We did a phase 2, randomised, double-blind, placebo-controlled, dose-escalation trial of intravenous multipotent adult progenitor cells in 33 centres in the UK and the USA. We used a computer-generated randomisation sequence and interactive voice and web response system to assign patients aged 18–83 years with moderately severe acute ischaemic stroke and a National Institutes of Health Stroke Scale (NIHSS) score of 8–20 to treatment with intravenous multipotent adult progenitor cells (400 million or 1200 million cells) or placebo between 24 h and 48 h after symptom onset. Patients were ineligible if there was a change in NIHSS of four or more points during at least a 6 h period between screening and randomisation, had brainstem or lacunar infarct, a substantial comorbid disease, an inability to undergo an MRI scan, or had a history of splenectomy. In group 1, patients were enrolled and randomly assigned in a 3:1 ratio to receive 400 million cells or placebo and assessed for safety through 7 days. In group 2, patients were randomly assigned in a 3:1 ratio to receive 1200 million cells or placebo and assessed for safety through the first 7 days. In group 3, patients were enrolled, randomly assigned, and stratified by baseline NIHSS score to receive 1200 million cells or placebo in a 1:1 ratio within 24–48 h. Patients, investigators, and clinicians were masked to treatment assignment. The primary safety outcome was dose-limiting toxicity effects. The primary efficacy endpoint was global stroke recovery, which combines dichotomised results from the modified Rankin scale, change in NIHSS score from baseline, and Barthel index at day 90. Analysis was by intention to treat (ITT) including all patients in groups 2 and 3 who received the investigational agent or placebo. This study is registered with ClinicalTrials.gov, number NCT01436487. Findings The study was done between Oct 24, 2011, and Dec 7, 2015. After safety assessments in eight patients in group 1, 129 patients were randomly assigned (67 to receive multipotent adult progenitor cells and 62 to receive placebo) in groups 2 and 3 (1200 million cells). The ITT populations consisted of 65 patients who received multipotent adult progenitor cells and 61 patients who received placebo. There were no dose-limiting toxicity events in either group. There were no infusional or allergic reactions and no difference in treatment-emergent adverse events between the groups (64 [99%] of 65 patients in the multipotent adult progenitor cell group vs 59 [97%] of 61 in the placebo group). There was no difference between the multipotent adult progenitor cell group and placebo groups in global stroke recovery at day 90 (odds ratio 1·08 [95% CI 0·55–2·09], p=0·83). Interpretation Administration of multipotent adult progenitor cells was safe and well tolerated in patients with acute ischaemic stroke. Although no significant improvement was observed at 90 days in neurological outcomes with multipotent adult progenitor cells treatment, further clinical trials evaluating the efficacy of the intervention in an earlier time window after stroke (<36 h) are planned. Funding Athersys Inc.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
刚刚
liuqi完成签到,获得积分10
1秒前
活泼的源完成签到,获得积分10
1秒前
2秒前
黄毛虎发布了新的文献求助10
4秒前
4秒前
李爱国的应助被misscloud采纳,获得10
4秒前
4秒前
敬祝完成签到,获得积分10
5秒前
5秒前
牟慕完成签到,获得积分10
6秒前
追寻纲发布了新的文献求助10
6秒前
6秒前
执着不二发布了新的文献求助10
7秒前
null的应助被聂志鹏采纳,获得10
7秒前
tang完成签到,获得积分10
7秒前
ttt完成签到,获得积分10
7秒前
8秒前
8秒前
9秒前
9秒前
9秒前
9秒前
星火发布了新的文献求助10
9秒前
9秒前
9秒前
9秒前
9秒前
9秒前
米米发布了新的文献求助10
9秒前
端庄向雁完成签到 ,获得积分10
9秒前
深情的灵寒完成签到,获得积分10
10秒前
文静千凡完成签到,获得积分10
10秒前
棒棒羊完成签到,获得积分10
10秒前
10秒前
长风赴宴发布了新的文献求助10
11秒前
Ki发布了新的文献求助10
11秒前
12秒前
13秒前
时光完成签到,获得积分10
14秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8186961
求助须知:如何正确求助?哪些是违规求助? 9575251
关于积分的说明 21840386
捐赠科研通 7784685
什么是DOI,文献DOI怎么找? 3434897
关于科研通互助平台的介绍 2559301
邀请新用户注册赠送积分活动 2481759